QHP Capital has appointed Owen Murray as the new CEO of the combined Bend Bioscience, CoreRx, and Societal entities. Murray joins the company from Aprecia Pharmaceutical, where he served as CEO.
 
With over 25 years of experience in the pharmaceutical and healthcare industries, Murray brings extensive expertise spanning early product development through commercialization. Prior to his role at Aprecia, he held various senior positions at Cardinal Health, Lundbeck, Ovation Pharmaceuticals, and Recordati Rare Diseases. His experience in both the EU and US markets has equipped him with a profound understanding of global markets and regulatory dynamics.
 
He holds a B.Sc. in Biochemistry with honors from the University of Wales, Swansea, an MBA with a management concentration from Seton Hall University, and an MS in Healthcare Leadership from Brown University.
 
“I am thrilled to join the company and both lead and unite our established Bend, CoreRx, and Societal businesses,” Murray shared. “Our goal is to offer exceptional service to the global pharmaceutical industry.”